At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 8, 2026 at 16:02 ET
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed). The company had $257.6 million in cash as of June 30, 2026, and expects cash runway into the second half of 2028. The modest buyback signals capital return but is not transformative given the clinical-stage status and limited program progress.
- $5 million share repurchase authorized
- $20 million milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed)
- Cash and cash equivalents of $257.6 million as of June 30, 2026
- Cash runway expected into second half of 2028 after milestone and buyback
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access